Today, South Korea's Sewon Cellontech Ltd. sign a landmark agreement with UCL Business PLC and the Royal National Orthopaedic Hospital NHS Trust (RNOH) to set up a joint-venture company, establishing a laboratory to concentrate on clinical cell therapeutic treatments for cartilage repair and bone fracture healing. (Left Picture) Mike Spyer, Vice Provost (Enterprise), UCL ; Chang Cheong-Ho, Chairman, Sewon Cellontech Co. Ltd; and Donald Hoodless, Chairman, RNOH ; (Right Picture) Cengiz Tarhan, Managing Director, UCL Business PLC; Martin Ferguson-Pell, Director of Research & Development, RNOH; Henry Kwon, Vice President, Sewon Cellontech Co. Ltd.; Chang Cheong-Ho, Chairman, Sewon Cellontech Co. Ltd.; Andrew Woodhead, Chief Executive, RNOH; Howard Klevens, International Consultant, Sewon Cellontech Co. Ltd.; Mike Spyer, Vice Provost (Enterprise), UCL; and UCL President and Provost Professor Malcolm Grant

It is hoped that this new joint-venture company will lead to the creation of a new technologically advanced enterprise that will be of benefit to the UK’s knowledge-driven economy, and it is expected that these therapies will lead to significant cost savings for the NHS through a reduction in patient recovery times and rehabilitation costs, also giving patients an enhanced quality of life

This new venture represents another significant endorsement by overseas bio-pharma companies of UCL’s status as one of the world’s leading universities. ,

Of the new partnership, Professor Mike Spyer commented, “The transfer of knowledge for the benefit of the community is a high priority for UCL. We believe a developing partnership with Sewon Cellontech, through the creation of a JV company will lead to positive outcomes for the University and society in general”.

Cengiz Tarhan, MD for UCLB, added further that “it is extremely gratifying to bring together the research base of UCL, the translational research being conducted at RNOH and the very encouraging patient applications of Sewon Cellontech’s products to create an opportunity for the benefit of all”.

These sentiments were echoed by Mr. Cheong Ho-Chang who said, “Regenerative medical systems are for the whole world. We wish to advance the field of cell therapy to bridge the gap between pure research and patient wellbeing and we are pleased to partner with UCL in this regard”.

Sewon Cellontech

Sewon Cellontech has grown and developed consistently maintaining its reputation as a leading engineering company since established in the early 1970's as a pioneer of heavy chemical industry in Korea. From our strong foothold, Sewon Cellontech has completed about 1700 domestic and international projects over past 30 years and has been devoting its utmost efforts toward creating the world's top brand based on innovative technologies from accumulated experience and "Value, Innovation & Creation and Passion" which are required to be a global leader in the 21st century. The company currently retains its own world top-class products in the bio-tech area of Life Engineering and also maintains world class technology including 5 representative products in petrochemistry and plant areas of Chemical Engineering.
Web: www.cellontech.com

View all news items